Redmile Group, LLC 的 Form 4 申報
ADC Therapeutics SA（ADCT），2024/12/13 申報
- 申報編號
- 0001104659-24-128575
- 申報時間
- 2024/12/13 21:00 ET
- 交易日
- 2024/12/11
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 4 筆非衍生性交易。公開市場買進合計 $60.9 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Redmile Group, LLCCIK 0001425738 | 持股 10% 以上大股東 |
| Green JeremyCIK 0001650527 | 持股 10% 以上大股東 |
| RedCo II Master Fund, L.P.CIK 0001921783 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/12/11 | Common Shares, par value CHF 0.08 per share | P買進取得 | +50,000 | $2.28F1 | +$114,000 | 15,616,731 | 間接 | |
| 2024/12/11 | Common Shares, par value CHF 0.08 per share | P買進取得 | +50,000 | $3.81F2 | +$190,500 | 15,666,731 | 間接 | |
| 2024/12/11 | Common Shares, par value CHF 0.08 per share | P買進取得 | +50,000 | $2.28F1 | +$114,000 | 13,095,712 | 直接 | |
| 2024/12/11 | Common Shares, par value CHF 0.08 per share | P買進取得 | +50,000 | $3.81F2 | +$190,500 | 13,145,712 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.165 to $2.4, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.64 to $3.9, inclusive. The Reporting Persons undertake to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
表 I 有 2 筆交易的價格引用這則附註。
備註
The purchases reported herein were effected within a period of less than six months from deemed sales reported in the Form 4 filed by the Reporting Persons on December 6, 2024. However, the purchases reported herein were effected at a price higher than the previous deemed sales that were also reported in the Form 4 filed December 6, 2024, such that no profits have been earned by the Reporting Persons, and so the Reporting Persons have no additional liability under Section 16(b).